Tuesday, 1 July 2008

Aspen's IP deal

Reported in today's Business Report is news that Africa's largest drug maker Aspen Pharmacare has purchased four GlaxoSmithKline (GSK) products, according to group chief executive Stephen Saad. Aspen's international subsidiary, Aspen Global, paid £170 million (R2.7 billion) for the intellectual property rights to Eltroxin, Imuran, Lanoxin and Zyloric for all major markets except the US and Japan. For the full report click here.

No comments: